MGNX MacroGenics Inc.

-0.19  -1%
Previous Close 19.08
Open 19.08
Price To Book 3.79
Market Cap 921460264
Shares 48,780,321
Volume 757,728
Short Ratio
Av. Daily Volume 1,647,148

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 interim data released at ASH December 2018. ORR 26%; CR 19%.
Phase 3 data released February 6, 2019 met primary endpoint. BLA filing due 2H 2019.
Margetuximab SOPHIA study
Metastatic breast cancer
Phase 2/3 trial to be initiated 2H 2019.
Margetuximab in combination with pembrolizumab
Gastric cancer
Phase 1 data at SITC November 2018.
Solid tumors
Phase 1 partial clinical hold lifted January 25, 2019.
Solid tumors
Phase 1 data due 2019.
Solid tumors
Phase 1 trial initiated 4Q 2018.
Solid tumors

Latest News

  1. MacroGenics to Participate in Upcoming Investor Conferences
  2. Edited Transcript of MGNX earnings conference call or presentation 26-Feb-19 9:30pm GMT
  3. Why MacroGenics Stock Rocketed 70.5% Higher in February
  4. Investor Expectations to Drive Momentum within LPL Financial, Comcast, MacroGenics, Wayfair, Masimo, and Big Lots — Discovering Underlying Factors of Influence
  5. Macrogenics Inc (MGNX) Q4 2018 Earnings Conference Call Transcript
  6. MacroGenics Provides Update on Corporate Progress and 2018 Financial Results
  7. MacroGenics Announces Participation in SVB Leerink Global Healthcare Conference
  8. Could MacroGenics, Inc.’s (NASDAQ:MGNX) Investor Composition Influence The Stock Price?
  9. Frontier Communications' (FTR) Q4 Earnings: What's in Store?
  10. Key Factors to Know Ahead of TransEnterix (TRXC) Q4 Earnings
  11. MacroGenics Announces Date of Fourth Quarter and Full Year 2018 Financial Results Conference Call
  12. Will Leasing Support SBA Communications' (SBAC) Q4 Earnings?
  13. HMS Holdings (HMSY) to Report Q4 Earnings: What's in Store?
  14. What's in Store for Telefonica Brasil (VIV) in Q4 Earnings?
  15. Key Factors Likely to Shape CVS Health's (CVS) Q4 Earnings
  16. Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars
  17. MacroGenics' Public Offering to Raise Funds for R&D, Marketing Is a Smart Move
  18. MacroGenics to Participate in Guggenheim Healthcare Talks Idea Forum
  19. The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering
  20. MacroGenics Announces Pricing of Public Offering of Common Stock